RAC

5.59%

$1.70 race oncology ltd

Does this also mean that RAC itself might now be unable to get...

First 6 Last

Share
Profile

Follow
IndexInvestor

8,390 Posts.

1383

07/07/24

14:55

Post #: 74643192
Share

Originally posted by RaceOncology: ↑

A very good question. While bisantrene the molecule is out of patent, our new RC220 formulation (i.e. the drug product) is not. What we have been able to do is reformulate bisantrene so that the problem of crystallisation in the blood that caused it to be abandoned by the original developer (Lederle), has been solved.

This process is very similar to what Abraxis did with Taxol to create Abraxane - they reformulated Taxol to solve the solubility issues with the original formulation and went on to sell billion of dollars worth of Abraxane over the past couple of decades. Reformulation to solve drug problems can be very profitable if done intelligently. Here is a link to some of the history of Abraxane.

https://stabiopharma.com/where-it-all-began-how-007-became-abraxane/

The obvious follow up question is won't someone just start selling the old formulation once our new formulation of bisantrene is approved? The answer is no for two reasons:

1. The old formulation is not FDA or EMA approved. Any developer of the old formulation would have to spend tens of millions dollars to bring the old formulation to market, but as soon as they brought it to market the generic drug manufacturers could start selling the own version of the old formulation and the price would immediately fall to that of a generic drug. No company will invest all the money required to develop the original formulation of bisantrene if they will face immediate generic competition.

2. Even if some company is crazy enough to spend all the money required to get the old formulation of bisantrene approved, no doctors or patients are going to participate in any of the trials need for approval. You can’t run a clinical trial of a worse version of an approved drug that offers no benefit to the patient - it would be unlikely that you could even get ethics approval to run such a trial.

This same priniciple applies to a different formulation of bisantrene. Unless this new formulation offered some significant clinical benefit over our RC220 formulation then it can’t be trialed and hence approved. This is exactly what happened with Abraxane which did not face any direct competition until the original formulation patents ended and the generic manufacturers could start making it.

Expand

Does this also mean that RAC itself might now be unable to get ethics approval to run a RC110 trial (not that RAC is planning to do so)?

Last edited by IndexInvestor: Today, 14:56

RAC Price at posting: $1.70 Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

STN

Saturn’s stars have aligned for the gold explorer’s Apollo Project

The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

LLL

Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng

ITM

Fast-track assaying yields 182 g/t gold for iTech at new NT play

KGL

KGL sniffs 19% Cu from drilling at Rockface play in NT

Week 27 Wrap: "Election year" is here as UK Labour win contrasts France; Trump wins immunity & annual report season hushes ASX

TVN

Tivan and EARTH AI gear up to commence fresh drilling at Sandover lead-silver project, NT

Climate change to drive market trends to the moon

RHI

Red Hill Minerals Signs $6.5 Million Agreement with Peel Mining to Explore Curnamona Project, NSW

There are more pages in this discussion • 11 more messages in this thread...

First 6 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.70		Change 0.090(5.59%)		Mkt cap ! $289.5M

Open	High	Low	Value	Volume
$1.60	$1.76	$1.59	$142.7K	84.97K

Buyers (Bids)

No.	Vol.	Price($)
2	17175	$1.70

Sellers (Offers)

Price($)	Vol.	No.
$1.77	6060	1

View Market Depth

No.	Vol.	Price($)
1	6000	1.700
2	2998	1.670
1	5000	1.665
3	3736	1.625
1	5000	1.615

Price($)	Vol.	No.
1.770	6060	1
1.820	9999	1
1.830	15000	1
1.840	1499	1
1.850	2500	2

Last trade - 16.10pm 05/07/2024 (20 minute delay)

RAC (ASX) Chart

Does this also mean that RAC itself might now be unable to get...

Saturn’s stars have aligned for the gold explorer’s Apollo Project

The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng

Fast-track assaying yields 182 g/t gold for iTech at new NT play

KGL sniffs 19% Cu from drilling at Rockface play in NT

Week 27 Wrap: "Election year" is here as UK Labour win contrasts France; Trump wins immunity & annual report season hushes ASX

Tivan and EARTH AI gear up to commence fresh drilling at Sandover lead-silver project, NT

Climate change to drive market trends to the moon

Red Hill Minerals Signs $6.5 Million Agreement with Peel Mining to Explore Curnamona Project, NSW

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Does this also mean that RAC itself might now be unable to get...

Top Stories

Saturn’s stars have aligned for the gold explorer’s Apollo Project

The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng

Fast-track assaying yields 182 g/t gold for iTech at new NT play

KGL sniffs 19% Cu from drilling at Rockface play in NT

Week 27 Wrap: "Election year" is here as UK Labour win contrasts France; Trump wins immunity & annual report season hushes ASX

Tivan and EARTH AI gear up to commence fresh drilling at Sandover lead-silver project, NT

Climate change to drive market trends to the moon

Red Hill Minerals Signs $6.5 Million Agreement with Peel Mining to Explore Curnamona Project, NSW

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News